Advertisement

Picture ConsulTech GmbH Forschungszulage 650x80px
Organisation › Details

Nabriva Therapeutics plc (Nasdaq: NBRV)

Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics’ medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics’ lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics believes lefamulin is well-positioned for use as a first-line empiric monotherapy for the treatment of moderate to severe CABP due to its novel mechanism of action, targeted spectrum of activity, resistance profile, achievement of substantial drug concentration in lung tissue and fluid, oral and IV formulations and a favorable tolerability profile. Nabriva Therapeutics is exploring potential further development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use. Nabriva Therapeutics owns exclusive, worldwide rights to lefamulin, which is protected by composition of matter patents issued in the U.S., Europe and Japan. *

 

Period Start 2017-05-23 restructured
  Group Nabriva (Group)
  Predecessor Nabriva Therapeutics AG
Products Industry anti-infective drug
  Industry 2 lefamulin (BC-3781)
Person Person Schroeder, Ted (Nabriva 201807– CEO before Zavante Therapeutics + Cadence Pharmaceuticals + Élan)
     
  Street 25–28 North Wall Quay IFSC
  City Dublin 1
  Tel +353-1-649-2000
    Address record changed: 2019-08-20
     
Basic data Employees D: 101 to 500 (2019-01-31)
  Currency USD
  Annual sales 9,656,000 (revenues, total, consolidated (2018) 2018-12-31)
  Profit -114,780,000 (2018-12-31)
  Cash 102,003,000 (2018-12-31)
     
    * Document for �About Section�: Nabriva Therapeutics plc. (9/20/17). "Press Release: Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference". Dublin & King of Prussia, PA.
     
   
Record changed: 2019-12-24

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Nabriva (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [iito] No Content Marketing 650x80px




» top